{
    "Clinical Trial ID": "NCT02115984",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Chemotherapy & Panagen",
        "  Chemotherapy: Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.",
        "  Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the preparation immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).",
        "INTERVENTION 2: ",
        "  Chemotherapy & Placebo",
        "  Chemotherapy: Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.",
        "  Placebo tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the placebo tablets immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy)."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Signed and dated written informed consent",
        "  Women at an age of 18 years",
        "  Stage II-IV breast cancer (with distant metastases)",
        "  The patients will be subject to chemotherapy with cyclophosphan/doxorubicin/ fluorouracil as a standard chemotherapy for treating breast cancer",
        "  The patients have not been earlier subject to chemotherapy",
        "  Functional status according to the Eastern Cooperative Oncology Group (ECOG) 2",
        "  Leukocyte counts of 3 \u00d7 109/L before the treatment course",
        "  Neutrophil counts of 1.5 \u00d7 109/L before the treatment course",
        "  Platelet counts of 100 \u00d7 109/L before the treatment course",
        "  Adequate heart function",
        "  Adequate liver function, that is, alanine aminotransferase / aspartate aminotransferase (ALT / AST) activity < 2.5 \u00d7 upper limit of normal (ULN); acid phosphatase activity < 5 \u00d7 ULN; and bilirubin concentration < 5 \u00d7 ULN; and",
        "  Adequate renal function, that is, the creatinine concentration in the blood serum < 1.5 \u00d7 ULN; urea concentration < ULN; and endogenous creatinine clearance",
        "Exclusion Criteria:",
        "  Participation in clinical trials less than 30 days before sequential randomization",
        "  Previous exposure to Panagen or any other leukostimulatory drugs at a stage of clinical development",
        "  Known hypersensitivity to cyclophosphan, doxorubicin, or fluorouracil",
        "  Therapy with systemically active antibiotics less than 72 h before the beginning of chemotherapy",
        "  Long-term oral intake of corticosteroids",
        "  Previous X-ray therapy performed less than 4 weeks before randomization",
        "  Previous transplantation of hematopoietic stem cells",
        "  Other malignant neoplasms during the last 5 years except for basal cell or flat cell carcinoma or intraepithelial carcinoma of the uterine cervix",
        "  Any disease or state that according to the opinion of researcher can influence patient's safety or the estimation of a final trial point; and",
        "  Pregnant and nursing women; the fertile patients should use chemical or barrier contraceptives during the period of trials"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  The Quantity of Leukocytes and Neutrophils in the Blood of Patients",
        "  [Not Specified]",
        "  Time frame: Baseline, Day 21 after 2nd chemotherapy (Day 42 post-baseline), Day 21 after 3rd chemotherapy (Day 63 post-baseline)",
        "Results 1: ",
        "  Arm/Group Title: Chemotherapy & Panagen",
        "  Arm/Group Description: Chemotherapy: Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.",
        "  Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the preparation immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).",
        "  Overall Number of Participants Analyzed: 51",
        "  Median (Inter-Quartile Range)",
        "  Unit of Measure: 10^9 cells/L  Leukocytes baseline: 8.1        (6.5 to 8.8)",
        "  Leukocytes after the 2nd chemotherapy: 6.6        (5.9 to 7.2)",
        "  Leukocytes after the 3rd chemotherapy: 5        (4.6 to 5.5)",
        "  Neutrophils baseline: 5.33        (4.42 to 6.36)",
        "  Neutrophils after the 2nd chemotherapy: 4.62        (3.43 to 4.82)",
        "  Neutrophils after the 3rd chemotherapy: 3.19        (1.81 to 3.58)",
        "Results 2: ",
        "  Arm/Group Title: Chemotherapy & Placebo",
        "  Arm/Group Description: Chemotherapy: Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.",
        "  Placebo tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the placebo tablets immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).",
        "  Overall Number of Participants Analyzed: 16",
        "  Median (Inter-Quartile Range)",
        "  Unit of Measure: 10^9 cells/L  Leukocytes baseline: 7.2        (6.5 to 7.9)",
        "  Leukocytes after the 2nd chemotherapy: 4.8        (4.1 to 5.6)",
        "  Leukocytes after the 3rd chemotherapy: 4.1        (3.8 to 4.4)",
        "  Neutrophils baseline: 5.2        (4.2 to 6.05)",
        "  Neutrophils after the 2nd chemotherapy: 2.76        (2.22 to 3.27)",
        "  Neutrophils after the 3rd chemotherapy: 2.44        (2.31 to 2.63)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 57/57 (100.00%)",
        "  Dry eyes  13/33 (39.39%)",
        "  Heartburn  9/33 (27.27%)",
        "  Nausea after the CT (before day 7)  57/57 (100.00%)",
        "  Herpetic eruption  0/33 (0.00%)",
        "  Dry skin  15/33 (45.45%)",
        "  Alopecia  57/57 (100.00%)",
        "Adverse Events 2:",
        "  Total: 23/23 (100.00%)",
        "  Dry eyes  2/11 (18.18%)",
        "  Heartburn  2/11 (18.18%)",
        "  Nausea after the CT (before day 7)  23/23 (100.00%)",
        "  Herpetic eruption  3/11 (27.27%)",
        "  Dry skin  9/11 (81.82%)",
        "  Alopecia  23/23 (100.00%)"
    ]
}